Daniel Portik

Radiation Oncologist | RTQA Fellow @EORTC | SF&Fantasy Reader | Google Reviews Writer | Wannabe Meme Artist

[Daniel Portik @PortikDaniel]

@_rahatmalhotra_ @jryckman3

[Daniel Portik @PortikDaniel]

Rare are such moments, but it makes them the more special.

[Yüksel Ürün @DrYukselUrun]

This is not simply a new pancreatic cancer drug.

It is a reminder that even “undruggable” biology can become treatable with persistence.

Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[Jeff Ryckman @jryckman3]

T-REX has quite a generous NI margin: Non-inferiority is declared if the de-escalation arm is not more than 4.5 percentage points worse than standard regional RT. This corresponds to an HR of about 1.41, assuming 88% 5-year RFS with standard treatment. #OncTwitter #BCSM #ASCO26

[Daniel Portik @PortikDaniel]

@drdavidpalma It's a data protection joke.

[Nat Lester-Coll, MD @DrLesterColl]

#ESTRO26 @cancerphysicist APHRODITE trial: EDRT (62Gy SIB) boosted 6-mo cCR to 49.4% vs 33.3% with SDRT in early rectal cancer (+16%; OR 2.27, p=0.038). First RCT evidence for dose escalation benefit + low toxicity!

[David Palma, MD, PhD @drdavidpalma]

This is a great thread about OLIGOMA.

I would just add that we can't expect phase III data for each histology. Two large histology-specific phase III trials (HN and esophagus) just closed due to poor accrual.

For SABR-COMET the strongest predictor of accrual was the level of equipoise of the referring physicians. Sometimes the referring physicians do not support randomization, which makes it difficult for us to do so.

https://t.co/EFDLruns2W

[David Sher @DavidSherMD]

JCOG 1208 is a nice study of ENI dose (46 Gy/23 fx) and volume reduction, without any solitary elective neck failures; another trial that supports ENI de-intensification.

However, we cannot be satisfied with 79% locoregional PFS, especially for oropharyngeal cancer.

Even with T1-2 N0-1 disease, sometimes concurrent chemotherapy may be needed.

[Daniel Portik @PortikDaniel]

@piet_ost @TylerSbrt @PCaParker @urotoday @neerajaiims @huntsmancancer @TDorffOnc @cityofhope @ChrisSweens1 @DrSpratticus @Prof_Nick_James @BertrandTOMBAL This has to go up on a wall, in a frame.

[Daniel Portik @PortikDaniel]

Accurate.

[JT @jiratickets]

How those first few minutes of the morning hit before you inevitably have to open a Microsoft application

[Piet Ost @piet_ost]

1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.

[Jeff Ryckman @jryckman3]

@DawnsMission Needle biopsies are standard because knowing exactly what you’re treating overwhelmingly outweighs the exceedingly small risks. Major reviews do not show increased metastasis from routine biopsy. Fear-based misinformation harms real patients.

[Drew Moghanaki @DrewMoghanaki]

Provocative finding from the EA5181 study shared by @JoeChangMD at #TexasLung26. The in-field progression rate after the PACIFIC regimen is only in the single digits. A statistic that needs to be on the scale when surgical resection of N2 disease is considered.

cc @MARIANOPROVENCI @FordePatrick @DrJNaidoo @gerryhanna @RamalingamMD @teekayowo

[Daniel Portik @PortikDaniel]

Just when you thought you cannot be surprised anymore:

[Michael @endpointarena]

Quick run down of the features on Endpoint Arena, the prediction market for clinical trials.

the home page has all the trials:

[Daniel Portik @PortikDaniel]

@jryckman3 @TheLancet One of my takeaways is: can we stop for a minute to appreciate how good IMRT has become?

[David Palma, MD, PhD @drdavidpalma]

Say hello to Srón! It's our new 3D-printed head for teaching nasopharyngoscopy.

(Srón means nose in Irish, pronounced "shrone")

You can print Srón yourself for free, or order one from us, at https://t.co/HJYfyrHXVk

[Daniel Portik @PortikDaniel]

Very honoured to have taken part on this long endeavour covering so many topics led by @cancerphysicist and @71Rianne . It was truly a learning experience!

[ESTRO @ESTRO_RT]

📗 Just published in the @RO_GreenJournal: ESTRO technical #guideline: intensity modulated radiotherapy and image guided radiotherapy for #rectalcancer
👉 Read the abstract: https://t.co/eHVTtTgxfu
#IMRT #IGRT

[Linus ✦ Ekenstam @LinusEkenstam]

The Olympic drone pilots are the best thing that happened the games, unsung heroes, period.

The coverage this year is officially on another level. We can finally feel so much closer to the action, it's pure magic, unreal.

Is it just me, or is this the best upgrade in years?

[Daniel Portik @PortikDaniel]

@DrewMoghanaki Birds of a feather, flock together.
Or we are whom we spend time with.

If we are in bubbles, we only hear our own ideas. We need to get our voices out there to our neighbouring specialities.

[Adam B. Weiner, MD @Adam_Weiner535]

🚀 MDT in oligometastatic #ProstateCancer 🚀

👉WOLVERINE IPD meta-analysis in @TheLancetOncol

🧪 7 randomized trials, 574 pts
📉 MDT → ↓ progression, ↓ radiographic progression, ↓ time to CRPC
🔁 Consistent benefit across SOC (obs, ADT, ARPI)
🛡️ Low toxicity, short treatment courses
⚖️ OS not definitive; but this is the strongest evidence yet to integrate MDT

👏 @ChadTangMD @piet_ost

🔗 to study https://t.co/OtIHw4RGgV
🔗 to editorial https://t.co/aeWi3Wx0ms

@PCFnews @urotoday @UrologyTimes

[Daniel Portik @PortikDaniel]

A win for video games!

[European Commission @EU_Commission]

Update on European Citizens’ Initiatives:

🔹 “Stop Destroying Videogames” has reached the required threshold and is now under Commission examination

🔹 Explore all officially registered initiatives, including the newest one from this week.

More: https://t.co/Mdn36U8xi0